Highlights
- 1British journal of anaesthesia · 2023
- 2Neurobiology of pain (Cambridge, Mass.) · 2023
- 3
Publications
79 publications
Funding
9 grantsView NIH portfolio on RePORTER ↗
Active
1 grant- PIR61NS147892-01Human(h) HCN1-selective nanobodies for use in the development of novel, non-opioid antihyperalgesics for the treatment of neuropathic painNational Institute of Neurological Disorders and Stroke · 2026–2028
Completed grants (8)
- Sub-PIR42NS129370-02Optimization of an HCN1-selective inverse agonist for the treatment of peripheral neuropathic painNational Institute of Neurological Disorders and Stroke · 2022–2025 · via Akelos, Inc.
- PIUG3NS114947-01Novel HCN1-selective small molecule inhibitors for the treatment of neuropathic painNational Institute of Neurological Disorders and Stroke · 2019–2022
- Co-ISRA 202653-01EPICC-NetNational Institute of Neurological Disorders and Stroke · 2020–2022 · via The General Hospital Corporation (dba Massachusetts General Hospital)Contract
- Co-ISRA 204842-01EPPIC-NETThe General Hospital Corporation (dba Massachusetts General Hospital) · 2020–2022Contract
- PISRA 192930-03Development of Novel Non-Narcotic Analgesics Through Targeting HCN1 Channels for Treatment of Peripheral Neuropathic Pain: A New Therapeutic ParadigmAkelos, Inc. · 2018–2021Contract
- PIDFI 183549-01Novel Non-Opioid Anti-Hyperalgesics for the Treatment of Peripheral Neuropathic PainDaedalus Fund for Innovation (Weill Cornell) · 2018–2019
- PIW81XWH-15-1-0279Novel Non-Anesthetic Alkylphenols for the Treatment of Neuropathic PainU.S. Department of Defense · 2015–2018
- PIR01GM066840-05Anesthetic Effects on Thalamic Synaptic TransmissionNIGMS · 2004–2008 · via NIH RePORTER
News mentions
2 mentionsView all WCM news ↗
- NIH Grant Awarded to Continue Non-Opioid Pain Medication ResearchNovember 4, 2026
The grant will enable researchers to study a new approach for delivering an experimental non-opioid pain medication, called BP4L-18:1:1, to relieve neuropathic pain.
- Potential Neuropathic Pain Treatment Shows Promise in Preclinical TestsAugust 9, 2023
A non-opioid designer molecule for treating chronic neuropathic pain by calming hyperactive pain-sensing neurons in the peripheral nervous system has had promising results in a preclinical study.
External relationships
Ownership
Akelos, Inc
Advisory/Scientific Board Member
Akelos, Inc
Proprietary Interest
Akelos, Inc